Phio Pharmaceuticals Corp. Company Profile
NASDAQ: PHIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Phio Pharmaceuticals at a glance
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in King of Prussia, PA. Phio Pharmaceuticals is led by Mr. Robert J. Bitterman and employs about 6 people. At a market capitalization of $7.8 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001533040, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Phio Pharmaceuticals do?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Phio Pharmaceuticals Corp.
- Ticker
- NASDAQ: PHIO
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert J. Bitterman
- Employees
- 6
- Headquarters
- 411 Swedeland Road, King of Prussia, PA, United States
- Phone
- 610 947 0251
- Website
- phiopharma.com
- Market cap
- $7.84M
- SEC CIK
- 0001533040
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to Phio Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLRBCellectar Biosciences Inc. | 0.797 | -11.50% | $8.00M | vs PHIO |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs PHIO |
| VTGNVistagen Therapeutics Inc. | 0.1636 | -12.33% | $7.56M | vs PHIO |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs PHIO |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs PHIO |
| RKTORocket One Inc. | 0.297 | +5.24% | $7.39M | vs PHIO |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs PHIO |
| IMRNImmuron Limited ADR | 0.8998 | +5.80% | $7.26M | vs PHIO |